Neo Ivy Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Neo Ivy Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$106K	Buy	+3,366	New	+$99.3K	0.02%	296
2026 Q1	–	Sell	-78,530	Closed	-$1.83M	–	371
2025 Q4	$1.83M	Buy	78,530 +57,314	+270%	+$1.28M	0.29%	126
2025 Q3	$418K	Sell	21,216 -104,411	-83%	-$2.15M	0.1%	248
2025 Q2	$2.73M	Buy	+125,627	New	+$2.97M	0.87%	20
2025 Q1	–	Sell	-35,652	Closed	-$744K	–	311
2024 Q4	$744K	Buy	+35,652	New	+$766K	0.15%	160

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neo Ivy Capital Management's CPRX Position: Q2 2026 in Review

Neo Ivy Capital Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 3,366 shares worth $106K. The stake represents 0.02% of the portfolio and ranks #296 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in CPRX as recently as Q4 2025.

Neo Ivy Capital Management first reported a position in CPRX in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.73M in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Neo Ivy Capital Management held 3,366 shares of Catalyst Pharmaceutical worth $106K as of Q2 2026.
Catalyst Pharmaceutical was a new Neo Ivy Capital Management position in Q2 2026.
Catalyst Pharmaceutical made up 0.02% of Neo Ivy Capital Management's portfolio in Q2 2026, its #296 holding.
Neo Ivy Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 5 quarters since.
Neo Ivy Capital Management's Catalyst Pharmaceutical position peaked at $2.73M in Q2 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.